Prognostic factors and effect on survival of immune-related adverse events in patients with non-small-cell lung cancer treated with immune checkpoint blockage
Conde-Estévez D, Monge-Escartín I, Ríos-Hoyo A, Monzonis X, Echeverría-Esnal D, Moliner L, Duran-Jordà X, Taus Á, Arriola E. Prognostic factors and effect on survival of immune-related adverse events in patients with non-small-cell lung cancer treated with immune checkpoint blockage. Journal Of Chemotherapy 2020, 33: 32-39. PMID: 33267748, DOI: 10.1080/1120009x.2020.1849488.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsAgedAntineoplastic Agents, ImmunologicalBody Mass IndexCarcinoma, Non-Small-Cell LungFemaleHospitals, UniversityHumansImmune Checkpoint InhibitorsLung NeoplasmsMaleMiddle AgedPrognosisProgression-Free SurvivalProportional Hazards ModelsRetrospective StudiesSex FactorsSocioeconomic FactorsConceptsImmune-related adverse eventsImmune checkpoint inhibitorsNon-small-cell lung cancerAdverse eventsCharacteristics of immune-related adverse eventsDevelopment of immune-related adverse eventsNSCLC patients treated with immune checkpoint inhibitorsPatients treated with immune checkpoint inhibitorsImmune-related adverse events occurrenceTreated with immune checkpoint inhibitorsImmune checkpoint blockageTreated with nivolumabSecond-line settingThirty-one patientsAssociated with improved patient outcomesCheckpoint inhibitorsMedian OSPrognostic factorsImprove patient outcomesGrade 3Lung cancerPatientsPatient outcomesThirty-oneMonths